Crispr Stem & Therapeutics (CST)
Gene and Cell Therapy for Acute Myocardial Ischemia
StartupCrispr Stem & Therapeutics (CST) is a Petah Tikva-based startup in the Health Tech & Life Sciences sector, established in 2018. Gene and Cell Therapy for Acute Myocardial Ischemia. The company has raised a total of $100K across 1 funding round, currently at the Pre-Funding stage. Crispr Stem & Therapeutics (CST) was founded by Dr. Dalia El-Ani. The company has 1-10 employees. Core technologies: Biologicals, Cells, Genes.
With $100K in total funding, Crispr Stem & Therapeutics (CST) is a Pre-Funding-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQPetah Tikva
- DistrictCenter District
- Last Round$100K
Dr. Dalia El-AniFounder & CEO
What does Crispr Stem & Therapeutics (CST) do?
Crispr Stem & Therapeutics (CST) is developing a patented cardio-protective CRISPR-based stem cell protocol to restrict the damage to the heart following acute heart attack and chronic heart failure. The company's technology will use CRISPR to genetically modify the patient's own stem cells, which are then treated by Crispr Stem & Therapeutics protocol and implanted in the patient with acute ischemic heart disease. The company's protocol was tested in several proof-of-concept experiments both in vitro and in vivo in animal models and showed dramatically decreased damage to the heart. The protocol aims to increase patients' life expectancy and quality of life, enable quick recovery, shorten hospitalization, and eliminate the risk of rejection. The company received recognition from the Israeli Innovation Authority (Tnufa funding) and European Commission with two Seals of Excellence.
How much funding has Crispr Stem & Therapeutics (CST) raised?
Crispr Stem & Therapeutics (CST) has raised $100K in total funding across 1 rounds. The company is currently at the Pre-Funding stage.
Who founded Crispr Stem & Therapeutics (CST)?
Crispr Stem & Therapeutics (CST) was founded in 2018 by Dr. Dalia El-Ani (Founder & CEO).
What sector is Crispr Stem & Therapeutics (CST) in?
Crispr Stem & Therapeutics (CST) operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells, Genes. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Biotechnology.
Where is Crispr Stem & Therapeutics (CST) located?
Crispr Stem & Therapeutics (CST) is based in Petah Tikva, Israel, Center District.